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Several experimental data have shown a relevant involvement of Nerve Growth Fac-
tor (NGF) in neoplastic proliferation and survival. NGF acts through two receptors and 
two distinct transduction pathways: high affinity TrKA receptor connected to prolifera-
tion via AKT, and low-affinity p75 receptor connected to apoptosis via caspases.
Our previous studies have shown that TrKA inhibitors have a relevant anti-prolifer-
ative effects in neoplasia. GW441756 is a novel TrKA-inhibitor (IC50 = 2nM) that displays 
an higher selectivity on TrKA respect to previous inhibitors and a 100-fold selectivity 
over a range of other kinases. However, its biological effects in cancer cells is still un-
known.
The aim of our study was to investigate in vitro the biological effects of this new 
inhibitor in human muscle sarcoma cancer cell line HTB114, at basal condition and fol-
lowing GW441756 administration.
As revealed by thymidine incorporation, GW441756 induced a dose-dependent de-
crease in neoplastic proliferation. Contemporaneously, Annexin V assay demonstrated 
a dramatic dose-dependent increase in apoptosis. 
To further characterize these results, we studied AKT and caspases activation by 
cytofluorimetric analysis. In agreement to its anti-proliferative-pro-apoptotic effects, 
GW441756 did not induce AKT activation, but produced a relevant increase of caspase-3 
that, in turn, leads to apoptosis.
In conclusion, GW441756 has a comparable anti-neoplastic effect respect to previ-
ous TrKA inhibitors, but with a lower effective dosage (10 μM vs 50 μM of other TrKA-
inhibitors). Our data have a preclinical relevance to achieve anti-proliferative effects in 
muscular sarcomas by TrKA-inhibitors administration.
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